Sirolimus Clinical Trials (44 Recruiting)

Showing 1–20 of 46 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome

City of Hope Medical Center15 enrolled1 locationNCT06287944

Recruiting

Phase 1Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Chronic Granulomatous Disease

National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT05463133

Recruiting

Phase 2

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

Arteriovenous Malformations

Centre Hospitalier Universitaire, Amiens50 enrolled13 locationsNCT02042326

Recruiting

Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more

National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839

Recruiting

Phase 2

Methods of T Cell Depletion Trial (MoTD)

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+6 more

University of Birmingham400 enrolled17 locationsNCT04888741

Recruiting

Phase 2

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more

University of Calgary12 enrolled1 locationNCT03214354

Recruiting

Phase 1Phase 2

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms

National Cancer Institute (NCI)430 enrolled1 locationNCT05327023

Recruiting

Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Hematologic NeoplasmsHematologic Malignancies

National Cancer Institute (NCI)155 enrolled1 locationNCT07162038

Recruiting

Phase 1Phase 2

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Hematologic Neoplasms

National Cancer Institute (NCI)320 enrolled2 locationsNCT04959175

Recruiting

Phase 1Phase 2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation

National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418

Recruiting

Phase 1Phase 2

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

X-linked Myotubular Myopathy

Astellas Gene Therapies9 enrolled4 locationsNCT07052929

Recruiting

Phase 2

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Familial Platelet DisorderHematopoietic

M.D. Anderson Cancer Center6 enrolled1 locationNCT06261060

Recruiting

Phase 1Phase 2

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD)X-Linked Chronic Granulomatous Disease

National Institute of Allergy and Infectious Diseases (NIAID)10 enrolled1 locationNCT06325709

Recruiting

Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more

Stanford University77 enrolled1 locationNCT05088356

Recruiting

Phase 1Phase 2

Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study

CD40L-HyperIgM Syndrome

National Institute of Allergy and Infectious Diseases (NIAID)1 enrolled1 locationNCT06959771

Recruiting

Phase 1Phase 2

Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome

CTNNB1 Neurodevelopmental Syndrome

CTNNB1 Foundation12 enrolled1 locationNCT07270549

Recruiting

Phase 1Phase 2

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)

National Cancer Institute (NCI)54 enrolled1 locationNCT06876142

Recruiting

Phase 2

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

Cerebral Aneurysm

University of Miami80 enrolled1 locationNCT04141020

Recruiting

Phase 2

Allo HSCT for High Risk Hemoglobinopathies

Sickle Cell DiseaseHemoglobinopathiesGraft Failure

Masonic Cancer Center, University of Minnesota62 enrolled1 locationNCT06872333

Sirolimus Clinical Trials

Advancing Transplantation Outcomes in Children

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Methods of T Cell Depletion Trial (MoTD)

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study

Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

Allo HSCT for High Risk Hemoglobinopathies